Media Alert: Tracking COVID-19 - Best and Worst Case Scenarios

By Kennen MacKay
Published March 27, 2020 | 4 min watch
Reports on the number of cases of Coronavirus continue to dominate news headlines around the world. Dr. Kennen MacKay, Managing Director and Co-Head of Biotechnology Research at RBC Capital Markets, joins CNBC’s Meg Tirrell to discuss best and worst case projection scenarios of COVID-19 in the U.S.
Kennen MacKay

Kennen MacKay
Managing Director, Co-Head of RBC Biotechnology Research

Dr. Kennen MacKay is a Managing Director at RBC and Co-Head of RBC Biotechnology Research. Kennen has over 10 years of biotechnology experience and previously covered the biotechnology sector at Credit Suisse and Citigroup. Prior to his career on Wall St., Kennen served as Director of the Michelson Prize and Grants under Los Angeles billionaire Dr. Gary Michelson, where he vetted biotechnologies for development in the non-profit setting. Kennen received his Ph.D. in Biochemistry and Molecular Biology from UCLA and his BA in Biochemistry from Colorado College, where he was a 4-yr Academic All-American on the swim team.

Coronavirus

Related Content